ValuEngine lowered shares of Marina Biotech (OTCMKTS:MRNA) from a hold rating to a sell rating in a research report report published on Friday morning.
Marina Biotech (MRNA) opened at $2.05 on Friday. Marina Biotech has a fifty-two week low of $1.03 and a fifty-two week high of $5.00.
COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/12/04/valuengine-lowers-marina-biotech-mrna-to-sell.html.
Marina Biotech, Inc is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases. The Company’s pipeline includes CEQ508, a product in clinical development for the treatment of Familial Adenomatous Polyposis (FAP), and preclinical programs for the treatment of type 1 myotonic dystrophy (DM1) and Duchenne muscular dystrophy (DMD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Marina Biotech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Marina Biotech Inc. and related companies.